Navigation Links
XOMA to Present at the Rodman and Renshaw Annual Global Investment Conference on November 11
Date:11/4/2008

BERKELEY, Calif., Nov. 4 /PRNewswire-FirstCall/ -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of antibody therapeutics, announced today that Steve Engle, Chairman and CEO of XOMA, is scheduled to present at the Rodman and Renshaw Annual Global Investment Conference. The presentation will take place in New York on November 11, 2008 at 9:55 AM EST.

An audio webcast of the presentation will be available live http://www.wsw.com/webcast/rrshq14/xoma and on the XOMA website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available for 90 days following the presentation.

About XOMA

XOMA discovers, develops and manufactures therapeutic antibody and other agents designed to treat inflammatory, autoimmune, infectious and cancerous diseases and is engaged in more than 13 active development projects. The Company's expanding pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 629, a synthetic antimicrobial peptide compound derived from bactericidal/permeability-increasing protein.

XOMA's proprietary development pipeline is primarily funded by multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations, and biodefense contracts. XOMA's technologies and experienced team have contributed to the success of marketed antibody products, including RAPTIVA(r) (efalizumab) for chronic moderate to severe plaque psoriasis, LUCENTIS(r) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(r) (certolizumab pegol) for Crohn's disease.

The Company has a premier antibody discovery and development platform that incorporates leading antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression technologies. Bacterial cell expression is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses.

In addition to developing its own products, XOMA develops products with premier pharmaceutical companies including Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of 330 employees at its Berkeley location. For more information, please visit http://www.xoma.com.

Certain statements contained herein relating to product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties regarding the status of biotechnology patents; uncertainties as to the cost of protecting intellectual property; changes in the status of the existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; market demand for products; scale up and marketing capabilities; competition; international operations; share price volatility; XOMA's financing needs and opportunities; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.

Contacts:

Media & Investors Contact:

Carolyn Hawley

Porter Novelli Life Sciences for XOMA

619-849-5375

chawley@pnlifesciences.com


'/>"/>
SOURCE XOMA Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
5. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
6. AtriCure to Present at Roth Capital Partners 2007 New York Conference
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. MDS to Present at Thomas Weisel Partners Healthcare Conference
9. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
10. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s ... finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , ... Judith Coats and Dr. David Coats. In September of 1983, they flew to ...
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: a ... Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor of Word ... bachelor degree in religious education and a master degree in theology. , ““The Octagon ...
(Date:1/24/2017)... Arlington, Va. (PRWEB) , ... January 23, 2017 ... ... (H.R. 592) was reintroduced on Friday, January 20, with the bipartisan original co-sponsorship ... 109) was re-introduced on January 12. The National Association of Chain Drug Stores ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... Texas with the acquisitions of two personal care service companies: Padre Home Health ... Texas, effective January 1, 2017. , Well regarded in their respective markets, these ...
(Date:1/24/2017)... ... 24, 2017 , ... The National Council of Alcoholism and Drug Dependence ( ... worked with communities to designate the last full week of January as National Drug ... “Shatter the Myths.” As a community, we can advocate for effective treatment, but ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... , Jan. 23, 2017 Endo International ... Trade Commission (FTC) today filed a joint motion in ... California seeking the entry of ... Order resolves all disputes between the FTC and Endo ... in connection with its Opana® ER and Lidoderm® products.  ...
(Date:1/23/2017)... CLARA, Calif. , Jan. 23, 2017 /PRNewswire/ ... protection market, Frost & Sullivan recognizes Ansell, a ... Global Frost & Sullivan Company of the Year ... customer-centric approach, and a wide global footprint have ... in the hand protection market. The Company,s established ...
Breaking Medicine Technology: